Skip to content

A randomized controlled study of a mobile medical APP-based treatment strategy for tuberculosis patients

A multi-center, open-labeled, randomized, parallel-group, equivalence study to compare the efficacy of a mobile medical APP-based tuberculosis case management strategy versus the standard strategy in the treatment of rifampicin-susceptible tuberculosis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037575
Enrollment
Unknown
Registered
2020-08-28
Start date
2020-11-01
Completion date
Unknown
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary tuberculosis (TB)

Interventions

Experimental group:Management using a mobile medical APP-based tuberculosis case management strategy
Control group:Management using the standard tuberculosis case management strategy

Sponsors

Shanghai Municipal Center for Disease Control and Prevention
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed TB patients as per the Chinese national standard of diagnosis for TB (TB pleurisy excluded); 2. Sensitive to rifampicin by GeneXpert. 2. Aged >= 18 years; 3. Willing to accept the standard anti-TB regimen (using first-line anti-TB drugs for 6 months) and treatment management; 4. Eligible for the use of mobile medical APP; 5. Willing to participate in the study.

Exclusion criteria

Exclusion criteria: 1. The treatment was more than 6 months; 2. With comorbidities such as HIV, malignant tumor, renal failure, liver cirrhosis and mental, audio, visual and language impairment; 3. With family member who had enrolled in the study; 4. Ineligible for the use of the mobile medical APP; 5. Planned to leave the study area within 18 months.

Design outcomes

Primary

MeasureTime frame
Poor treatment outcomes over 18 months from start of TB treatment, including death, failure, loss to followup and relapse;

Secondary

MeasureTime frame
Percentage of months in which the patient missed at least 20% of doses;Percentage of total doses missed;

Countries

China

Contacts

Public ContactZheyuan Wu

Shanghai Municipal Center for Disease Control and Prevention

wuzheyuan@scdc.sh.cn+86 13512120670

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026